Prostate cancer survivors make up the largest group, 41 percent, of male cancer survivors. In these survivors, early detection of recurrence can lead to life-saving interventions, but in older men who ...

Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Researchers from Korea say that inpatient prostate-specific antigen (PSA) levels should be ignored for the purposes of serial monitoring, after finding that they are significantly reduced compared ...

Editor's note: second of two parts; read part one here. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms.

Prostate-specific antigen (PSA) is one of the few molecular markers routinely used for detection, risk stratification and monitoring of a common cancer. PSA is specific to the prostate but not to ...

The purpose of this study was to determine if early PSA velocity (EPSAV), drawn from PSA values within normal ranges, predicts the later occurrence of abnormally high PSA values or positive prostate ...